Naringin promotes differentiation of bone marrow stem cells into osteoblasts by upregulating the expression levels of microRNA-20a and downregulating the expression levels of PPARγ

JIFENG FAN, JIE LJ and QINBO FAN

Department of Orthopedics, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China

Received September 26, 2014; Accepted May 28, 2015

DOI: 10.3892/mmr.2015.3996

Abstract. Naringin is a dihydrotestosterone flavonoid compound that significantly inhibits bone loss, improves bone density, and enhances biomechanical anti-compression performance. Previous studies have demonstrated that naringin improves the activity levels of osteocalcin (OC) and alkaline phosphatase (ALP) in MC3T3-E1 osteoblast precursor cells. The present study investigated the effects of naringin on osteoblastic differentiation and inhibition of adipocyte formation in bone marrow stem cells (BMSCs). The levels of osteogenesis were modulated via upregulation of the expression levels of microRNA (miR)-20a, and downregulation of the expression levels of peroxisome proliferator-activated receptor γ (PPARγ). The results indicated that naringin significantly enhanced BMSC proliferation in a dose-dependent manner. In addition, naringin significantly increased the mRNA expression levels of OC, ALP, and collagen type I. Furthermore, naringin decreased the protein expression levels of PPARγ, and increased the expression levels of miR-20a in the BMSCs. These results suggested that miR-20a may regulate the expression of PPARγ in BMSCs. To our knowledge, this is the first study to report naringin-induced osteogenesis via upregulation of the expression levels of miR-20a, and downregulation of the expression levels of PPARγ. These results indicated the important role of naringin in BMSC differentiation.

Introduction

Bone marrow stem cells (BMSCs) are currently under active investigation due to their therapeutic potential for bone tissue engineering and cell replacement therapy (1). BMSCs were initially described in 1966, when they were isolated and cultured from bone marrow rat cartilage cells (2). A previous study showed that BMSCs migrate toward damaged bone tissue, thereby demonstrating the therapeutic potential of BMSCs for tissue injury repair and cell replacement therapy (3). In addition, BMSCs have been reported to survive in high hypoxic/ischemic inflammatory environments (4). The present study aimed to investigate the mechanism underlying BMSC migration, as well as the role of BMSCs in tissue repair-associated protein regulation. This was achieved by modulating BMSC motility and viability through genetic engineering (5,6).

Peroxisome proliferator activated receptor γ (PPARγ) is a subtype of PPAR, which mediates BMSC differentiation into adipocytes (7). PPARγ is a ligand-activated nuclear transcription factor, which is involved in cellular differentiation, growth, and apoptosis (8). PPARγ mediates the differentiation of BMSCs into adipocytes, and an increase in the protein expression levels of PPARγ results in a significant increase in adipocyte differentiation, concomitant with reduced levels of osteogenic differentiation, in the bone marrow (9). Therefore, PPARγ may prove useful in the treatment and prevention of osteoporosis, a disease in which deregulated BMSC differentiation, dedifferentiation, and transdifferentiation leads to a decrease in the number of osteoblasts, and an increase in the number of adipocytes (10).

Micro (mi)RNAs are small (19-22 nucleotides) endogenous non-coding RNA molecules, which suppress the expression of target genes (11). miRNAs have an important role in numerous biological processes, including cellular proliferation, differentiation, and apoptosis. Previous studies have shown that the upregulation of miR-20a expression leads to an increase in the protein expression levels of the adipogenic PPARγ marker gene in rats, as compared with the controls (12,13).

Naringin is a dihydrotestosterone flavonoid compound, which markedly inhibits bone loss, improves bone density, and enhances biomechanical anti-compression performance (14). Naringin has been shown to promote the proliferation and differentiation of MC3T3-E1 osteoblast precursor cells in vitro; however, it does not promote bone mineralization (15). High concentrations of naringin increase the synthesis and activity levels of alkaline phosphatase (ALP), promote osteoblast...
differentiation, and stimulate bone formation (16). A previous study demonstrated that naringin increases the activity levels of osteocalcin (OC) and ALP, and promotes the proliferation and differentiation of MC3T3-E1 osteoblast precursor cells, without affecting bone mineralization (16).

The present study aimed to investigate whether naringin was able to enhance BMSC differentiation and inhibit adipocyte formation by modulating osteogenesis via the upregulation of miR-20a expression, and the downregulation of PPARγ expression.

Materials and methods

Drugs and reagents. Naringin (Fig. 1) at a purity >95% (Sigma-Aldrich, St Louis, MO, USA) was dissolved in physiological saline, according to the manufacturer's instructions. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco Life Technologies (Carlsbad, CA, USA), and Invitrogen Life Technologies (Carlsbad, CA, USA), respectively. MTT assay and Lipofectamine® 2000 were purchased from Sigma-Aldrich.

Animals and BMSC isolation. Male and female New Zealand white rabbits (4-8 weeks old) weighing 2.0±0.5 kg were provided by the Experimental Animal Center of Dalian Medical University (Dalian, China). The rabbits were maintained in individual cages at 21-23°C, under a 12 h light-dark cycle (8:00; 20:00) and humidity level of 55-65%. The study was approved by the ethics committee of The First Affiliated Hospital of Dalian Medical University (Dalian, China). The rabbits were anesthetized by intravenous injection of 30 mg/kg pentobarbital (Invitrogen Life Technologies). A total of 2-3 ml bone marrow was subsequently collected from the lateral tibial tubercle of the rabbits using a puncture needle. The bone marrow cell suspension was then mixed with an equal volume of Percoll solution and centrifuged at 1,000 x g for 10 min. The supernatant was discarded and the mononuclear BMSCs were extracted. The supernatant was discarded and the nonmononuclear BMSCs were extracted. The BMSCs were washed with phosphate-buffered saline (PBS) and further centrifuged at 1,000 x g for 10 min. The supernatant was discarded and 10 ml DMEM supplemented with 15-20% FBS was added to the precipitate, prior to incubation at 37°C in a humidified atmosphere containing 5% CO₂. The cells were cultured until they reached 80% confluence and were then used for subsequent experimentation.

Cell proliferation assay. The levels of BMSC proliferation were determined using an MTT assay. BMSCs were seeded at a density of 2.0x10⁴ cells/well into 96-well plates at 37°C in a humidified atmosphere containing 5% CO₂. The BMSCs were then treated with either 0.01, 0.1, 1, 10 and 100 µM naringin (17) for 48 h, or with medium containing 0, 0.1, 1, and 10 µM naringin for 3, 7, 14 and 21 days or with medium containing 0, 0.1, 1, and 10 µM naringin for 48 h. Total RNA was extracted from the BMSCs treated with TRIZol® reagent (Invitrogen Life Technologies). A total of 1 µg total RNA was subsequently reverse transcribed into cDNA using an RT-qPCR mixture (Takara Biotechnology Co., Ltd., Dalian, China). A 5 ng cDNA template was used to carry out the reaction. Various primers (Sangon Biotech Co., Ltd.) were used in order to amplify OC, ALP, and Col I (Table I). In order to determine the expression levels of miR-20a, the BMSCs were treated with 0.1, 1, and 10 µM naringin for 48 h. Total RNA containing miR-20a was extracted from the BMSCs using a mirNEasy RNA Isolation Kit (Bogoo Biomart, Shanghai, China). The expression levels of miR-20a were subsequently analyzed by RT-qPCR using a TaqMan® RT-qPCR system (7500 Real-Time PCR system; Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. PCR cycling conditions were as follows: 35 cycles at 95°C for 30 sec, 60°C for 45 sec and 72°C for 50 sec. The sequence of the miR-20a primer is shown in Table I. cDNA was reverse transcribed from 100 ng total miRNA using a Quantitect Reverse Transcription Kit (Bogoo Biomart). miRNA expression levels were determined using the 2ΔΔCt method of relative quantification.

Quantification of the protein expression levels of OC, ALP, collagen type I (Col I), and miR-20a by reverse transcription-quantitative polymerase chain reaction. In order to determine the mRNA expression levels of OC, ALP, and Col I, the BMSCs were treated with 1 µM naringin for 3, 7, 14 and 21 days or with medium containing 0, 0.1, 1, and 10 µM naringin for 48 h. Total RNA containing miR-20a was extracted from the BMSCs using a mirNEasy RNA Isolation Kit (Bogoo Biomart, Shanghai, China). The expression levels of miR-20a were subsequently analyzed by RT-qPCR using a TaqMan® RT-qPCR system (7500 Real-Time PCR system; Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. PCR cycling conditions were as follows: 35 cycles at 95°C for 30 sec, 60°C for 45 sec and 72°C for 50 sec. The sequence of the miR-20a primer is shown in Table I. cDNA was reverse transcribed from 100 ng total miRNA using a Quantitect Reverse Transcription Kit (Bogoo Biomart). miRNA expression levels were determined using the 2ΔΔCt method of relative quantification.

BMCSC transfection with miR-20a and anti-miR-20a. miR-20a precursor and anti-miR-20a (Ambion Life Technologies, Carlsbad, CA, USA) were synthesized by Sangon Biotech Co., Ltd. miR-20a precursor: 5’-GTAAGTGACGCTAAAGTGGC TTATAGTGCAAGTAGGTGTATAGTTATCTACTGCATTAT
GAGC ACT TAA AGT ACT GC-3'; and 3'-GCA GTACTTTAAGTGGCTATAATGCAGTAGATAAACTAAC ACTACCTGACTATAAGCACTTTTAGTGCTA-5'; anti-miR-20a, 5'-CTA A AC ACT ACC TGC ACT ATA AGCACTTTAGCTAC-3', and 5'-GAAAATGACTGCGG TGGAGACGTGTTGGCACCAGTAC-3'. The BMSCs were seeded into 6-well plates at 1.0-2.0x10^6 cells/well for 48 h in order to perform the transfection. The cells were transfected using Lipofectamine® 2000 with 100 ng miR-20a precursor, anti-miR-20a, or a negative precursor (pcDNA3.1+). After 24 h, the BMSCs were treated with 0.1, 1, and 10 µM naringin for 48 h. In all experiments untreated BMSCs were used as controls.

**Statistical analysis.** All statistical analyses were performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). The data are presented as the mean ± standard deviation. A χ² and exact probability test were performed in order to compare two groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Effects of naringin on the proliferation of BMSCs.** As shown in Fig. 2, naringin dose-dependently enhanced the proliferation of BMSCs. Following treatment with 0.1, 1, 10 and 100 µM naringin for 48 h, BMSC proliferation was significantly enhanced (Fig. 2A). In addition, treatment with 0.1, 1, and 10 µM naringin for 3-10 days significantly enhanced BMSC proliferation (Fig. 2B).

**mRNA expression levels of OC, ALP, and Col I in BMSCs.** BMSCs were treated with 1 µM naringin for 3, 7, 14 and 21 days. There was a significant increase in the mRNA expression levels of OC, ALP, and Col I in the naringin-treated BMSCs, as compared with the control group (Fig. 3A-3C). Following treatment with 1 µM naringin for 21 days, the mRNA expression levels of OC were the highest, with expression levels 5.8-fold greater, as compared with that of the control cells (Fig. 3A). The mRNA expression levels of ALP were increased by 2.3, 2.4, 3.9 and 2.9-fold following 3, 7, 14, and 21 days, respectively, as compared with the control group (Fig. 3B). The mRNA expression levels of Col I significantly increased between 14-21 days during osteogenic differentiation, as compared with the control group (Fig. 3C). In addition, BMSC treatment with 0.1, 1, and 10 µM naringin for 48 h significantly increased the mRNA expression levels of OC, ALP, and Col I (Fig. 3D).

**Protein expression levels of PPARγ in BMSCs.** Following treatment with 0, 0.1, 1 and 10 µM naringin for 48 h, the protein expression levels of PPARγ were analyzed by western blotting (Fig. 4A). Treatment with 1 and 10 µM naringin significantly decreased the protein expression levels of PPARγ, as compared with the control group (Fig. 4B). A χ² and exact probability test were performed in order to compare two groups. P<0.05 was considered to indicate a statistically significant difference.

**RT-qPCR analysis of miR-20a expression in BMSCs.** Following treatment with 0, 0.1, 1, and 10 µM naringin for 48 h, the expression levels of miR-20a in the BMSCs were analyzed by RT-qPCR. The expression levels of miR-20a were significantly increased in the BMSCs treated with naringin (1 and 10 µM), as compared with the control group (Fig. 5).

**Overexpression of miR-20a suppresses the expression levels of PPARγ in BMSCs.** In order to determine whether miR-20a regulates the protein expression of PPARγ in BMSCs, the
FAN et al: EFFECTS OF NARINGIN ON BONE MARROW STEM CELL DIFFERENTIATION

Figure 2. Effects of naringin on the proliferation of bone marrow stem cells (BMSCs). (A) Treatment with naringin enhanced the proliferation of BMSCs after 48 h in a dose-dependent manner. (B) Naringin concentrations ranging from 0.1-10 µM stimulated BMSC proliferation after 3-10 days. *P<0.01, vs. the control group.

Figure 3. mRNA expression levels of osteocalcin (OC), alkaline phosphatase (ALP) and collagen type I (Col I) in bone marrow stem cells (BMSCs). The mRNA expression levels of (A) OC, (B) ALP, and (C) Col I in the BMSCs following treatment with 1 µM naringin for 21 days. (D) Treatment with 0.1, 1, and 10 µM naringin for 48 h significantly increased the mRNA expression levels of OC, ALP, and Col I. **P<0.01, vs. the control group.

Figure 4. Protein expression levels of peroxisome proliferator-activated receptor γ (PPARγ). (A) Following treatment with 0, 0.1, 1, and 10 µM naringin for 48 h, the protein expression levels of PPARγ in the bone marrow stem cells (BMSC) were analyzed using western blot analysis. (B) Protein expression levels of PPARγ as determined by statistical analysis. **P<0.01, vs. the control group.
protein expression levels of PPARγ were analyzed in BMSCs post-transfection with a miR-20a precursor. The effects of the miR-20a precursor on the expression levels of miR-20a expression were analyzed by RT-qPCR. BMSC transfection with a miR-20a precursor significantly increased the expression levels of miR-20a in BMSCs (Fig. 6A). Conversely, the protein expression levels of PPARγ were significantly decreased following transfection with miR-20a (Fig. 6B).

Anti-miR-20a reverses the effects of naringin in BMSCs. Anti-miR-20a antibody was used to investigate the effects of miR-20a on the naringin-induced inhibition of BMSCs. BMSC transfection with anti-miR-20a antibody significantly reduced the expression levels of miR-20a in BMSCs (Fig. 7A). In addition, BMSC transfection with anti-miR-20a antibody also significantly reduced the effects of 1 µM naringin on the mRNA expression levels of OC in BMSCs (Fig. 7B), and
significantly increased the protein expression levels of PPAR{gamma} (Fig. 7C) at 48 h. These results suggest that the anti-miR20a may neutralize the inhibitory effects of naringin through the downregulation of miR-20a expression, and the upregulation of PPAR{gamma} expression in BMSCs (Fig. 7D).

Discussion

BMSCs are adult stem cells located in the bone marrow, which have high self-renewal and differentiation potentials (18). Although BMSCs have been isolated and cultured from numerous tissue types, such as the liver, embryonic blood, umbilical cord blood, and amniotic fluid, BMSCs are predominantly obtained from bone marrow tissues (19,20). In the bone marrow, BMSCs account for 0.001%-0.1% of the total cells, and exhibit high differentiation potential. Indeed, BMSCs are able to differentiate into adipocytes, bone cells, cartilage cells, and myoblasts (21). BMSCs have been isolated from the bone marrow in numerous species, including mice, rats, rabbits, and humans. The results of the present study demonstrated that naringin was able to dose-dependently enhance the proliferation of BMSCs, which prompted the further investigation of the therapeutic effects of naringin on BMSCs.

Osteoblasts determine not only the rate of bone formation, they also adjust the activity levels of osteoclasts, thereby determining the rate of bone resorption (22). Bone formation includes three stages: Osteoblast proliferation, osteoblast maturation, and mineralization of the extracellular matrix. Osteoblast proliferation is the bone formation step that predominantly determines the final amount of formed bone. ALP is an enzyme secreted during the differentiation of osteoblasts (16). The levels of ALP are correlated with the synthesis of Col I and with the formation of bone matrix; ALP therefore serves as a marker for the early and mid-stages of osteoblast differentiation (23). In addition, the activity levels of ALP are correlated with the activity levels of osteoclasts (24). Previous studies demonstrated that miR-20a, a downregulation of miR-20a expression, and the upregulation of PPAR{gamma} expression in BMSCs (Fig. 7D).

The results of the present study revealed that naringin is able to promote BMSC differentiation into osteoblasts, via the upregulation of miR-20a, and the downregulation of PPAR{gamma}. Thus suggesting that naringin may be a potential novel drug that may promote BMSC differentiation into osteoblasts, in the treatment of osteoporosis.

References


